Clinical Trials Browser

Completed × NSCLC × anlotinib × Clear all

NCT04691388 2024-12-05

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

Phase 2 Completed

NSCLC